If you have been reading about peptide backbone and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-03-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
瑞他鲁肽同时激活GLP-1受体、GIP受体和胰高血糖素受体,这三者均属于B类G蛋白偶联受体。受体激活后主要经cAMP信号通路传递效应。GLP-1成分与食欲抑制和胃排空延缓相关,GIP成分影响脂肪组织与胰岛素分泌,胰高血糖素成分则促进肝糖输出和能量消耗。各受体贡献的相对比例在人体中尚未完全量化。
该分子是经过结构修饰的合成肽,通过脂肪酸侧链与白蛋白结合,从而延长循环时间。皮下给药后,药物逐步释放并分布至组织。降解主要依赖蛋白酶,肾脏清除占次要地位。人体半衰期以天为单位,但准确数值随检测方法和个体差异而变;组织分布与受体占有率仍是开放问题。
临床研究通常测量体重、腰围、空腹血糖、糖化血红蛋白和血脂,并记录不良事件。药代动力学评估关注浓度-时间曲线,药效动力学评估关注代谢标志物变化。体重下降由能量摄入减少、能量消耗变化和脂肪组织重塑共同造成,具体权重仍不明确。研究之间的终点定义和随访时长差异使横向比较复杂。
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
| Property | Value | Notes |
|---|---|---|
| 分子量 | 约4.7 kDa | 合成肽,具体数值随形式而变化 |
| 外观 | 白色至类白色冻干粉 | 常见于多肽制剂 |
| 溶解度类别 | 水溶性 | 可溶于水性缓冲液,pH影响溶解 |
| 典型储存温度 | -20°C或更低 | 冻干粉长期保存 |
| 典型分析方法 | 反相高效液相色谱与质谱 | 用于纯度、身份和杂质分析 |
Characterization of retatrutide in research settings relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase separation resolves the parent peptide from related impurities, while electrospray ionization mass spectrometry confirms molecular mass against a calculated value. Peptide mapping after enzymatic digestion can verify the amino acid sequence. Laboratories often combine orthogonal methods because no single technique establishes both identity and purity. Detected impurities typically include truncated sequences, oxidized residues, and deamidated forms that arise during synthesis or storage.
Material handling focuses on limiting degradation. Lyophilized powder is generally stored at reduced temperature, often around minus twenty degrees Celsius, protected from light and moisture. Once dissolved, the peptide is less stable and is commonly kept cold and used within a short window. Repeated freeze-thaw cycles promote aggregation and should be avoided. Buffers and pH influence stability, and solution conditions are usually selected to keep the peptide near neutral pH where degradation proceeds more slowly. These practices apply to laboratory reference material, not to clinical preparations.
Verification of research-grade material depends on documentation supplied with a sample. A certificate of analysis lists purity, identity, and the methods used to establish each value. Buyers comparing suppliers look at chromatographic purity figures, mass confirmation data, and whether methods are described in enough detail to be reproduced. Independent testing can confirm reported values but adds cost and time. Because the research chemical market is not uniformly regulated, provenance and documentation quality vary widely, and claims should be evaluated against raw data rather than summary labels.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
In the pharmaceutical industry, a blockbuster drug is one that achieves acceptance by prescribing physicians as a therapeutic standard for, most commonly, a highly prevalent chronic (rather than acute) condition. Patients often take the medicines for long periods.
== Reactions == Having a pKa value of around 0, TFA does not exist as such at concentrations found in natural waters. Instead TFA converts to trifluoroacetate, concomitant with the protonation of water. It protonates several weakly basic anions, e.g. azide to give hydrazoic acid.
When not flying, bats hang upside down from their feet, a posture known as roosting. Most megabats roost with the head tucked towards the belly, whereas most microbats roost with the neck curled towards the back. This difference is due to the structure of the cervical or neck vertebrae in the two groups, which are clearly distinct. Tendons allow bats to hang from a roost with no effort, which is needed to release. Bats are more awkward when crawling on the ground, though a few species, such as the New Zealand lesser short-tailed bat (Mystacina tuberculata) and the common vampire bat (Desmodus rotundus), are quite agile. These species move their limbs one after the other, but vampire bats accelerate by bounding, the folded-up wings being used to propel them forward. Vampire bats likely evolved these gaits to stalk their hosts, while short-tailed bats took to the ground due to a lack of competition from other mammals. Terrestrial locomotion does not appear to affect their ability to fly.
There is, however, little research on whether female condoms are as effective as male condoms at preventing STIs, and they are slightly less effective than male condoms at preventing pregnancy, which may be because the female condom fits less tightly than the male condom or because it can slip into the vagina and spill semen. The vaginal lymph nodes often trap cancerous cells that originate in the vagina. These nodes can be assessed for the presence of disease. Selective surgical removal (rather than total and more invasive removal) of vaginal lymph nodes reduces the risk of complications that can accompany more radical surgeries. These selective nodes act as sentinel lymph nodes. Instead of surgery, the lymph nodes of concern are sometimes treated with radiation therapy administered to the patient's pelvic, inguinal lymph nodes, or both. Vaginal cancer and vulvar cancer are very rare, and primarily affect older women. Cervical cancer (which is relatively common) increases the risk of vaginal cancer, which is why there is a significant chance for vaginal cancer to occur at the same time as, or after, cervical cancer. It may be that their causes are the same. Cervical cancer may be prevented by pap smear screening and HPV vaccines, but HPV vaccines only cover HPV types 16 and 18, the cause of 70% of cervical cancers. Some symptoms of cervical and vaginal cancer are dyspareunia, and abnormal vaginal bleeding or vaginal discharge, especially after sexual intercourse or menopause. However, most cervical cancers are asymptomatic (present no symptoms).
Sources: en.wikipedia.org
=== Polymorphonuclear neutrophils === Within an hour of wounding, polymorphonuclear neutrophils (PMNs) arrive at the wound site and become the predominant cells in the wound for the first two days after the injury occurs, with especially high numbers on the second day. They are attracted to the site by fibronectin, growth factors, and substances such as kinins. Neutrophils phagocytise debris and kill bacteria by releasing free radicals in what is called a respiratory burst. They also cleanse the wound by secreting proteases that break down damaged tissue. Functional neutrophils at the wound site only have life-spans of around two days, so they usually undergo apoptosis once they have completed their tasks and are engulfed and degraded by macrophages. Other leukocytes to enter the area include helper T cells, which secrete cytokines to cause more T cells to divide and to increase inflammation and enhance vasodilation and vessel permeability. T cells also increase the activity of macrophages.
=== Other === Cosmetics; Medical makeup can temporarily conceal scars. This is most commonly used for facial scars. Dermabrasion involves the removal of the surface of the skin with special equipment, and usually involves a local anaesthetic. A 2012 literature review found weak evidence that massage was efficacious in scar management. Any beneficial effect appeared to be greater in wounds created by surgical incision than for traumatic or burn wounds. A 2022 scoping review covering twenty-five studies of 1515 participants reported that all studies reviewed reported favorable outcomes for scar massage, but that "while there may be benefits to scar massage in reducing pain, increasing movement and improving scar characteristics", there was a lack of "consistent research methods, intervention protocols and outcome measures". Microneedling
== External links == "Connective Tissue Disorders". National Library of Medicine. 2017-09-15. Dunkin, Mary Anne (2023-10-10). "Connective Tissue Disease: Types, Symptoms, Causes". WebMD. "Connective tissue diseases". DermNet®. 2023-10-26.
Sources: en.wikipedia.org
India Archived 11 January 2021 at the Wayback Machine. The World Factbook. Central Intelligence Agency. India web resources provided by GovPubs at the University of Colorado Boulder Libraries India from BBC News Wikimedia Atlas of India Geographic data related to India at OpenStreetMap Key Development Forecasts for India from International Futures
== Further reading == Khan, Misbah H.; Victor, Frank; Rao, Babar; Sadick, Neil S. (2010). "Treatment of cellulite. Part I. Pathophysiology". Journal of the American Academy of Dermatology. 62 (3): 361–70, quiz 371–2. doi:10.1016/j.jaad.2009.10.042. PMID 20159304. Khan, Misbah H.; Victor, Frank; Rao, Babar; Sadick, Neil S. (2010). "Treatment of cellulite. Part II. Advances and controversies". Journal of the American Academy of Dermatology. 62 (3): 373–84, quiz 385–6. doi:10.1016/j.jaad.2009.10.041. PMID 20159305.
== Additives == All automotive antifreeze formulations, including the newer organic acid (OAT antifreeze) formulations, are environmentally hazardous because of the blend of additives (around 5%), including lubricants, buffers, and corrosion inhibitors. Because the additives in antifreeze are proprietary, the safety data sheets (SDS) provided by the manufacturer list only those compounds which are considered to be significant safety hazards when used in accordance with the manufacturer's recommendations. Common additives include sodium silicate, disodium phosphate, sodium molybdate, sodium borate, denatonium benzoate, and dextrin (hydroxyethyl starch). Disodium fluorescein dye is added to conventional ethylene glycol formulas to visually distinguish leaked amounts from other vehicle fluids, and as a marker of type to distinguish it from incompatible types. This dye fluoresces bright green when illuminated by blue or UV light from daylight or testing lamps. Automotive antifreeze has a characteristic odor due to the additive tolyltriazole, a corrosion inhibitor. The unpleasant odor in industrial-use tolyltriazole comes from impurities in the product that are formed from the toluidine isomers (ortho-, meta-, and para-toluidine) and meta-diamino toluene which are side-products in the manufacture of tolyltriazole. These side-products are highly reactive and produce volatile aromatic amines which are responsible for the unpleasant odor.
== Reference pattern == Amino acid requirements were determined in two parts. The amino acid distribution of breast milk was used for the 0 to 6 month age range, and existing amino acid data was used for older ages after adjustment for digestibility. The reference amino acid requirements are presented below.
Sources: en.wikipedia.org
意味着单个分子可同时结合三种代谢受体,而不是只作用于一种。其目的是整合食欲、胰岛素和能量消耗通路,但人体中的协同程度仍在研究。
不是。研究还评估血糖控制、肝脏脂肪、血脂和心血管风险标志物。不同终点的证据成熟度不同。
胰高血糖素成分在人体中的净效应存在争议,因为它可能升高血糖,也可能增加能量消耗。长期平衡和个体差异尚未明确。
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.